Davis Polk advised the sole bookrunning manager in connection with the public offering of 3,500,000 shares of the common stock of Coherus BioSciences, Inc. at a price to the public of $18.00 per share. Coherus’s common stock is listed on the NASDAQ Global Market under the symbol “CHRS.”
Based in Redwood City, California, Coherus is a leading pure-play, global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets.
The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Hua Zhao and Ingrid L. Perez. The tax team included partner Rachel D. Kleinberg and associate Mahalia S. Burford. The intellectual property and technology team included associates Michelle Gross and Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.